CorrelAtes of Protective immuniTy-driven Investigation of malaria VAccine combin...
CorrelAtes of Protective immuniTy-driven Investigation of malaria VAccine combinaTion stratEgies
Malaria remains a serious health concern worldwide, with P. falciparum considered one of the deadliest human parasites. Yet, the currently approved vaccine against malaria (RTS,S/AS01) offers limited protection due to challenges i...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MultiMalVax
A Multi Stage Malaria Vaccine
8M€
Cerrado
SAF2008-00743
ESTUDIO DE MARCADORES DE INMUNIDAD Y SUSCEPTIBILIDAD FRENTE...
121K€
Cerrado
REDMAL
Clinical development of a Pfs48 45 based malaria transmissio...
5M€
Cerrado
SPARCL
Dissecting early Skin-based immune responses to PARasites in...
1M€
Cerrado
GENINVADE
Parasite population genomics and functional studies towards...
3M€
Cerrado
SAF2016-76080-R
CARACTERIZACION DE LOS GLICOCONJUGADOS PRESENTES EN LAS SUPE...
97K€
Cerrado
Información proyecto CAPTIVATE
Duración del proyecto: 53 meses
Fecha Inicio: 2023-11-01
Fecha Fin: 2028-04-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Malaria remains a serious health concern worldwide, with P. falciparum considered one of the deadliest human parasites. Yet, the currently approved vaccine against malaria (RTS,S/AS01) offers limited protection due to challenges in vaccine development. Using current advances made in understanding immunity to address some of the existing challenges, this proposal aims to develop a more efficacious vaccine against P. falciparum by targeting multiple developmental stages (sporozoite, liver and blood-stage). In this project, combinations of 1) highly promising whole parasite vaccination approach targeting the liver (late-arresting GAP), 2) RTS,S (provided by GSK) and 3) mRNA versions of clinically evaluated and partially protective blood stage vaccine candidates (Rh5, AMA1-DiCo [sporozoite and blood stage]) will be evaluated in preclinical and small-scale human trials to discern the optimal combination for further clinical investigations. To inform a rational design of future vaccine candidates, CAPTIVATE will analyse the vaccine-induced immune response to acquire a full understanding of malaria protective immunity and develop an advanced immunology in-silico platform. While immunity to blood stage malaria is relatively well understood, the mechanisms of adaptive protective immunity for pre-erythrocytic malaria vaccine candidates are less well-established. CAPTIVATE addresses this critical knowledge gap by combining state-of-the-art preclinical and clinical (CHMI) in vivo malaria vaccine efficacy models with an innovative in-silico platform comprising TCR/VDJ sequencing and artificial intelligence predictions, to identify such mechanisms. CAPTIVATE assembles a unique combination of European experts in their respective fields (malaria modelling in primates, clinical vaccine testing, in-silico modelling of immune responses, innovative omics approaches) in an integrated interdisciplinary approach aimed at bringing the next generation malaria vaccines to the clinic.